Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (35,874)	$ (29,990)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	42	20
Stock-based compensation expense	4,511	2,173
Amortization of premiums and accretion of discounts on marketable securities, net	(1,344)	575
Amortization of right-of-use asset	103	100
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(436)	2,058
Other assets	(38)	(78)
Accounts payable	(278)	996
Accrued clinical trial expenses	(1,151)	1,358
Operating lease liability	(103)	(100)
Accrued expenses and other current liabilities	(182)	(1,062)
Net cash used in operating activities	(34,750)	(23,950)
Cash flows from investing activities
Purchases of marketable securities	(178,857)	(12,129)
Proceeds from maturities and sales of marketable securities	55,997	71,860
Proceeds from sale of property and equipment	3	0
Purchases of property and equipment	(7)	(126)
Net cash provided by (used in) investing activities	(122,864)	59,605
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	122,294	0
Proceeds from exercise of stock options	325	19
Payments for deferred offering costs	0	(296)
Net cash provided by (used in) financing activities	122,619	(277)
Net change in cash and cash equivalents and restricted cash	(34,995)	35,378
Cash and cash equivalents and restricted cash at the beginning of the period	130,101	122,162
Cash and cash equivalents and restricted cash at the end of the period	95,106	157,540
Supplemental disclosure of noncash investing and financing activities
Proceeds from sale of property and equipment in other current assets	4	0
Right-of-use assets obtained in exchange for operating lease liabilities	0	233
Deferred offering costs in accrued expenses and other current liabilities	0	41
Reconciliation of cash, cash equivalents and restricted cash to the condensed balance sheets
Cash and cash equivalents	94,917	157,540
Restricted cash	189	0
Total cash, cash equivalents and restricted cash	$ 95,106	$ 157,540